BioSpace News Archive

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST.

Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil’s proprietary workflow to enhance the patient’s access to therapy.

Codagenix, Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today presented data from ongoing studies of their novel intranasal COVID-19 vaccine, COVI-VAC, at the IDWeek 2021 annual conference held virtually September 29-October 3.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351 in Chinese patients with solid tumors (ClinicalTrials.gov, NCT05005234) completed dosing of the first subject.

GenFleet Therapeutics, and Innovent Biologics (HKEX: 01801) today announced that the first patient with KRAS G12C mutation has been dosed in the first-in-human trial of GFH925 (ClinicalTrials.gov, NCT05005234).

Hangzhou Chance Pharmaceuticals, a clinical-stage biotechnology company focusing on discovering, developing, and commercializing transformative inhalation therapies for the world’s most debilitating diseases, announced that it has appointed Guobao Zhao as Senior Vice President responsible for business development and corporate strategy.